Quantitative results from the EMiT screen can also be used to determine the sample dilution required for confirmation procedures. This type of information not only makes the gas chromatographic/mass spectrometnc (GC/MS) confirmation process more efficient, but also, by comparing the screening concentration with the confirmed concentration, adds a measure of confidence to the certification process (3, 4). ' We investigated quantification of drugs in urine controls analyzed during the EMiT screening procedure. We limited our investigation to urine control materials containing specific drugs in five categories required for analysis by National Institute on Drug Abuse (N1DA)-certified laboratories, i.e., benzoylecgonine, morphine, methamphetamine, phencycidine (PCP), and cannabinoids (THC-9-acid). Our analytical approach must be evaluated within the expected limitations of quantification involving commercially available immunoassay reagents; these include (a) having some antibodies that react with more than one drug analyte, (b) having no control over the relative reagent concentrations, (c) being limited to reagents that are adapted to a specific instrument, and (d) having a limited number of calibrators for each drug class, as supplied by the manufacturer. Our primary aim was to develop a procedure for Received November 16, 1990; accepted March 6, 1991. 1Nonstandard abbreviations:
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MaterIals and Methods
The EMIT stock reagents were prepared according to the manufacturer's instructions, except that ethylene glycol, 250 g/L, in distilled water was substituted for distilled water in the reconstitution protocols. The EMIT buffer was prepared as specified by the EMiT To evaluate reagent stability from day 1 of the stability study, as well as to evaluate the efficacy of daily calibration, we used two calibration curves. One was generated on day 1 of the study, and a new one was generated each subsequent day. Alter calculating the daily assay results, the daily curve was deactivated, the original curve was called from software storage, and the drug concentrations were recalculated with use of the original calibration curve.
Results

Linearity
Calibrator #{163}4 values varied linearly with the log of drug concentration for all drugs. This linearity continued through an initial 10-day period of the study as indicated, e.g., by the overlapping curves shown for stimulants (Figure 1, top) . Despite a shift to lower #{163}4 values during the 10-day study period (Figure 1 , bottom), the THC-9-acid assay did not lose linearity. 
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Monarch 2000 from the single six-point calibration curves. The slope, intercept, and standard error of estimation for each calibration curve are given in Table 2 .
Precision
Within-run CVs were <5% for EMIT d.a.u. results when control specimens containing 40%, 100%, 120%, and 200% of the NIDA cutoff limits were assayed 10 times in one run (Table 3) , except for the PCP and THC-9-acid 40% controls. The analysis of all drugs was more precise at the 100% cutoff value than at the 40% value (P <0.005, F-test) .
The between-days precision of analyzing these same controls was determined by assaying each of the controls daily for 10 days, with both an original calibration curve (Table 4 ) and a new, daily calibration curve (data not shown). As expected, these data indicate a better precision after daily calibration than after a single calibration on day 1 for most drugs (P <0.005, F-test).
Daily calibration reduced the CVs for most drugs by about one-half of those obtained after only one calibration at the beginning of the stability study. Indeed, the CVs for THC-9-acid controls were reduced by one-third to one-seventh of those based on a single calibration.
Accuracy
The assays were calibrated according to the standard Monarch protocols with single determinations of calibrators that were reconstituted on day 1 and used for daily calibration until day 15 of the study. New calibrators (with the same lot number) were reconstituted on day 15 for THC-9-acid and on day 17 for the other four drugs; these calibrators were used for the remainder of the study. Mean control values obtained during the within-day precision study were within 10% of the target values for the 100% and 120% controls ( The THC-9-acid control values were much more variable, and the daily calculated results for THC-9-acid drifted to lower values during the first two weeks of the study. The apparent instability is confounded somewhat by the addition of new reagents on day 7 and the performance of a new calibration on day 15. Considering these changes in reagents and calibrators, the stability of THC-9-acid in this study would be best evaluated in increments: days 1-5, days 7-14, and days 15-30. Within each of these increments, the calculated values vary by 10%, and there is less drift for all controls after the new calibration on day 15 (Figure 2 ). There was less drift in the calculated control values when the assays calibrated each day were compared with calculations based on an original calibration curve (Figure 2, right panels) . The calculated values for benzoylecgonine, opiates, PCP, and stimulants remained within 10% of their values on day 1 of the study, except for the PCP 40% control (10 ig/L), which had values on some days as high as 14 ig/L. Daily calibration produced THC-9-acid control values that were closer to their targets than were the values obtained after only one calibration.
As indicated above, the variation observed for THC-9-acid control values was distorted somewhat by the addition of reagents on day 7 and the reconstitution of new calibrators on day 15. If the variation of THC-9-acid values is considered within the intervals of days 1-5, 7-14, and 15-30, the drift of control values was within 10%, except for the 200% control, which drifted upward during the first two weeks of the study.
Discussion
The nonlinear interpolation algorithm used by the Monarch 2000 for therapeutic drug assays provides a "good fit" calibration curve, as indicated by the regression data and by the accuracy of assigning positive or negative values to the 100% NIDA cutoff controls. However, as expected for immunoassay calibration curves, the error in the curve-fitting algorithm will be greatest at either end of the curve (5). This particular algorithm (for the Monarch 2000) also yielded a less precise analysis, with the deviation from target values being greatest at the low or high control values.
The precision of this quantitative approach is similar to that indicated for other quantitative procedures, including the Abbott TDx (6), RIA (7) and GC/MS (8,9), all of which have reported CVs of <5%. The lack of improvement in precision for some of the EMIT d.a.u. assays after daily calibration compared with monthly calibration supports the notion of day-to-day reagent stability, at least for the first three weeks after reagent preparation. The THC-9-acid assay is less stable and would require more frequent calibration, particularly after a change in reagents to promote consistent quality-control values.
Although the primary aim of this study was to determine the precision and stability of quantitative control values, we also found that the quantification algorithm could transform #{163}4 values into drug concentrations with some degree of accuracy. When the 100% NIDA control was calculated by the Monarch algorithm to be above or below the cutoff limit, the same positive or negative result was obtained after a qualitative comparison of respective #{163}4 values. Even for THC-9-acid, where the spread of calculated values was greatest, there were no discrepant values between a quantitative and a qualitative evaluation based on a daily calibration. This close agreement could be predicted because we used a "point-to-point" curve-fitting algorithm to compute a calibration curve that included one calibrator at the quantitative cutoff value. In contrast, if a "bestfit" regression algorithm (10) is used to construct the calibration curve, there is always some margin of error (albeit small in the case of a close curve fit) in calculating the concentration at the cutoff. Where the curve fit is poor, the possibility of disagreement between the quantitative and qualitative result is more likely.
In the absence of bias, one would expect an equal distribution of quantitative control values around the NIDA cutoff value. In this study, we found a slight positive bias for most drug quantifications, producing values for the 100% control that were 5-10% higher than the stated cutoff value. This bias is illustrated, e.g., in Figure 2 , in which only four of 30 THC-9-acid 100% based on data (Figure 1, bottom) showing parallel calibration curves for THC-9-acid that vary only by an increment in the y-intercept.
If one takes 40% of the NIDA cutoff limits as the limits of quantification, most of the calculated values would be precise to within 5% and would agree to within 10-20% of the target values. Based on this, the sensitivity of this assay is adequate for monitoring controls down to 40% of the NIDA cutoffs. Calibration curves constructed with use of EMIT reagents were linear up to 10-fold the NIDA cutoff values. This linearity compares well with the linearity demonstrated by the Abbott TDx system (12). Given the expectation that errors of estimation increase as the concentration of the analyte deviates from the midrange of the assay, one should expect that the CVs of controls with drug concentrations higher than twofold the NIDA cutoff limits might exceed 20%. Beyond their use in monitoring quality control, quantitative results from the EMIT screen may have some interesting uses during the confirmation of positive screening results. First, the drug concentration could be used to estimate the sample dilution required for confirmation procedures. 
